Drugs / SPIL1033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01406717 | Mar 2013 → Nov 2015 | type 2 diabetes mellitus | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPIL1033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01406717 ↗ |
| Route | Subcutaneous | “SPIL1033 is subcutaneous injection” NCT01406717 ↗ |